Plumbagin exhibits an anti‑proliferative effect in human osteosarcoma cells by downregulating FHL2 and interfering with Wnt/β‑catenin signalling

Xue,Yuan‑Liang; Meng,Xiang‑Qi; Ma,Long‑Jun; Yuan,Zhen

doi:10.3892/ol.2016.4725

Plumbagin exhibits an anti‑proliferative effect in human osteosarcoma cells by downregulating FHL2 and interfering with Wnt/β‑catenin signalling

Authors:
- Yuan‑Liang Xue
- Xiang‑Qi Meng
- Long‑Jun Ma
- Zhen Yuan
View Affiliations

Affiliations: Department of Orthopedics of Clinical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, P.R. China, Department of Orthopedics, Suzhou Hospital of Traditional Chinese Medicine, Suzhou, Jiangsu 215000, P.R. China, Department of Orthopedics, People's Hospital of Yangxin, Binzhou, Shandong 251800, P.R. China, Department of Orthopedics, Shandong Provincial Qianfoshan Hospital, Jinan, Shandong 250014, P.R. China
Published online on: June 15, 2016 https://doi.org/10.3892/ol.2016.4725
Pages: 1095-1100

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Plumbagin, a naphthoquinone constituent of Plumbago zeylanica L. (Plumbaginaceae) is widely used in traditional Chinese medicine as an antifungal, antibacterial and anti‑inflammatory agent. Plumbagin is known to exhibit proapoptotic, antiangiogenic and antimetastatic effects in cancer cells. The transcriptional co‑factor four and a half LIM domains 2 (FHL2) is a multifunctional adaptor protein that is involved in the regulation of gene expression, signal transduction and cell proliferation and differentiation, and also acts as a tumor suppressor or oncoprotein depending on the tissue microenvironment. The present study investigated the effect of plumbagin on FHL2 expression, Wnt/β‑catenin signalling and its anti‑proliferative activity in various human osteosarcoma cell lines, including SaOS2, MG63, HOS and U2OS. The cells were exposed to plumbagin and the expression of FHL2 was evaluated using western blot analysis. Furthermore, the anti‑proliferative effect of plumbagin was evaluated using a 3‑(4,5 dimethyl‑thiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide assay. In addition, since FHL2 is involved in Wnt/β‑catenin signaling, the effect of plumbagin on β‑catenin and its primary target genes, including v‑myc avian myelocytomatosis viral oncogene homolog (c‑Myc) and WNT1 inducible signaling pathway protein‑1 (WISP‑1), was evaluated using western blot analysis. It was observed that plumbagin suppressed the expression of FHL2 and exhibited significant anti‑proliferative activity in osteosarcoma cells. It also attenuated Wnt/β‑catenin signalling by downregulating β‑catenin and its target genes, including c‑Myc and WISP‑1. In conclusion, plumbagin demonstrated anti‑proliferative activity in osteosarcoma cells by downregulating FHL2 and interfering with Wnt/β‑catenin signalling.

View Figures

View References

1	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Pediatric and Adolescent Osteosarcoma. Jaffe N, Bruland OS and Bielack S: Springer; New York, NY: pp. pp3–13. 2009, View Article : Google Scholar
2	Guijarro MV, Ghivizzani SC and Gibbs CP: Animal models in osteosarcoma. Front Oncol. 4:1892014. View Article : Google Scholar : PubMed/NCBI
3	Luetke A, Meyers PA, Lewis I and Juergens H: Osteosarcoma treatment-where do we stand? A state of the art review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
4	Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M and Trent JM: Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell. 1:279–288. 2002. View Article : Google Scholar : PubMed/NCBI
5	Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M, Kristiansen G, Hsieh JC, Hofstaedter F, Hartmann A, et al: WIF-1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung and bladder cancer. J Pathol. 201:204–212. 2003. View Article : Google Scholar : PubMed/NCBI
6	Hoang BH, Kubo T, Healey JH, Yang R, Nathan SS, Kolb EA, Mazza B, Meyers PA and Gorlick R: Dickkopf 3 inhibits invasion and motility of SaOS-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res. 64:2734–2739. 2004. View Article : Google Scholar : PubMed/NCBI
7	Barker N and Clevers H: Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov. 5:997–1014. 2006. View Article : Google Scholar : PubMed/NCBI
8	Lin YC, You L, Xu Z, He B, Mikami I, Thung E, Chou J, Kuchenbecker K, Kim J, Raz D, et al: Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines. Biochem Biophys Res Commun. 341:635–640. 2006. View Article : Google Scholar : PubMed/NCBI
9	Huelsken J and Birchmeier W: New aspects of Wnt signaling pathways in higher vertebrates. Curr Opin Genet Dev. 11:547–553. 2001. View Article : Google Scholar : PubMed/NCBI
10	Mlodzik M: Planar cell polarization: Do the same mechanisms regulate Drosophila tissue polarity and vertebrate gastrulation? Trends Genet. 18:564–571. 2002. View Article : Google Scholar : PubMed/NCBI
11	Clevers H: Wnt/beta-catenin signaling in development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
12	Westendorf JJ, Kahler RA and Schroeder TM: Wnt signaling in osteoblasts and bone diseases. Gene. 341:19–39. 2004. View Article : Google Scholar : PubMed/NCBI
13	Rawadi G and Roman-Roman S: Wnt signalling pathway: A new target for the treatment of osteoporosis. Expert Opin Ther Targets. 9:1063–1077. 2005. View Article : Google Scholar : PubMed/NCBI
14	Haydon RC, Deyrup A, Ishikawa A, Heck R, Jiang W, Zhou L, Feng T, King D, Cheng H, Breyer B, et al: Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer. 102:338–342. 2002. View Article : Google Scholar : PubMed/NCBI
15	Reya T and Clevers H: Wnt signalling in stem cells and cancer. Nature. 434:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
16	Espada J, Calvo MB, Diaz-Prado S and Medina V: Wnt signaling and cancer stem cells. Clin Transl Oncol. 11:411–427. 2009. View Article : Google Scholar : PubMed/NCBI
17	Wu CL, Tsai HC, Chen ZW, Wu CM, Li TM, Fong YC and Tang CH: Ras activation mediates WISP-1-induced increases in cell motility and matrix metalloproteinase expression in human osteosarcoma. Cell Signal. 25:2812–2822. 2013. View Article : Google Scholar : PubMed/NCBI
18	Kadrmas JL and Beckerle MC: The LIM domain: From the cytoskeleton to the nucleus. Nat Rev Mol Cell Biol. 5:920–931. 2004. View Article : Google Scholar : PubMed/NCBI
19	Gabriel B, Fischer DC, Orlowska-Volk M, zur Hausen A, Schüle R, Müller JM and Hasenburg A: Expression of the transcriptional coregulator FHL2 in human breast cancer: A clinicopathologic study. J Soc Gynecol Investig. 13:69–75. 2006. View Article : Google Scholar : PubMed/NCBI
20	Wang J, Yang Y, Xia HH, Gu Q, Lin MC, Jiang B, Peng Y, Li G, An X, Zhang Y, et al: Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis. Gastroenterology. 132:1066–1076. 2007. View Article : Google Scholar : PubMed/NCBI
21	Amann T, Egle Y, Bosserhoff AK and Hellerbrand C: FHL2 suppresses growth and differentiation of the colon cancer cell line HT-29. Oncol Rep. 23:1669–1674. 2010.PubMed/NCBI
22	Martin B, Schneider R, Janetzky S, Waibler Z, Pandur P, Kühl M, Behrens J, von der Mark K, Starzinski-Powitz A and Wixler V: The LIM only protein FHL2 interacts with beta-catenin and promotes differentiation of mouse myoblasts. J Cell Biol. 159:113–122. 2002. View Article : Google Scholar : PubMed/NCBI
23	Zhang J, Cao H, Zhang B, Cao H, Xu X, Ruan H, Yi T, Tan L, Qu R, Song G, et al: Berberine potently attenuates intestinal polyps growth in ApcMin mice and familial adenomatous polyposis patients through inhibition of Wnt signalling. J Cell Mol Med. 17:1484–1493. 2013. View Article : Google Scholar : PubMed/NCBI
24	Kim JH, Kim YH, Song GY, Kim DE, Jeong YJ, Liu KH, Chung YH and Oh S: Ursolic acid and its natural derivative corosolic acid suppress the proliferation of APC-mutated colon cancer cells through promotion of β-catenin degradation. Food Chem Toxicol. 67:87–95. 2014. View Article : Google Scholar : PubMed/NCBI
25	Padhye S, Dandawate P, Yusufi M, Ahmad A and Sarkar FH: Perspectives on medicinal properties of plumbagin and its analogs. Med Res Rev. 32:1131–1158. 2012. View Article : Google Scholar : PubMed/NCBI
26	Xu TP, Shen H, Liu LX and Shu YQ: Plumbagin from Plumbago zeylanica L induces apoptosis in human non-small cell lung cancer cell lines through NF-kB Inactivation. Asian Pac J Cancer Prev. 14:2325–2331. 2013. View Article : Google Scholar : PubMed/NCBI
27	Sinha S, Pal K, Elkhanany A, Dutta S, Cao Y, Mondal G, Iyer S, Somasundaram V, Couch FJ, Shridhar V, et al: Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo. Int J Cancer. 132:1201–1212. 2013. View Article : Google Scholar : PubMed/NCBI
28	Hafeez BB, Zhong W, Fischer JW, Mustafa A, Shi X, Meske L, Hong H, Cai W, Havighurst T, Kim K and Verma AK: Plumbagin, a medicinal plant (Plumbago zeylanica)-derived 1,4-naphthoquinone, inhibits growth and metastasis of human prostate cancer PC-3M-luciferase cells in an orthotopic xenograft mouse model. Mol Oncol. 7:428–439. 2013. View Article : Google Scholar : PubMed/NCBI
29	Ahmad A, Banerjee S, Wang Z, Kong D and Sarkar FH: Plumbagin-induced apoptosis of human breast cancer cells is mediated by inactivation of NF-kappaB and Bcl-2. J Cell Biochem. 105:1461–1471. 2008. View Article : Google Scholar : PubMed/NCBI
30	Hsu YL, Cho CY, Kuo PL, Huang YT and Lin CC: Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. J Pharmacol Exp Ther. 318:484–494. 2006. View Article : Google Scholar : PubMed/NCBI
31	Hafeez BB, Zhong W, Mustafa A, Fischer JW, Witkowsky O and Verma AK: Plumbagin inhibits prostate cancer development in TRAMP mice via targeting PKCε, Stat3 and neuroendocrine markers. Carcinogenesis. 33:2586–2592. 2012. View Article : Google Scholar : PubMed/NCBI
32	Kuo PL, Hsu YL and Cho CY: Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol Cancer Ther. 5:3209–3221. 2006. View Article : Google Scholar : PubMed/NCBI
33	Gomathinayagam R, Sowmyalakshmi S, Mardhatillah F, Kumar R, Akbarsha MA and Damodaran C: Anticancer mechanism of plumbagin, a natural compound, on non-small cell lung cancer cells. Anticancer Res. 28:785–792. 2008.PubMed/NCBI
34	Ravindra KC, Selvi BR, Arif M, Reddy BA, Thanuja GR, Agrawal S, Pradhan SK, Nagashayana N, Dasgupta D and Kundu TK: Inhibition of lysine acetyltransferase KAT3B/p300 activity by a naturally occurring hydroxynaphthoquinone, plumbagin. J Biol Chem. 284:24453–24464. 2009. View Article : Google Scholar : PubMed/NCBI
35	Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M and Helman L: An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis. 18:261–271. 2000. View Article : Google Scholar : PubMed/NCBI
36	Davies EM: Protein assays: A review of common techniques. Am Biotech Lab. 6:28–37. 1988.
37	Legler G, Müller-Platz CM, Mentges-Hettkamp M, Pflieger G and Julich E: On the chemical basis of the Lowry protein determination. Anal Biochem. 150:278–287. 1985. View Article : Google Scholar : PubMed/NCBI
38	Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Folin Phenol Reagent. J Biol Chem. 193:267–275. 1951.
39	Jaffe N: Osteosarcoma: Review of the past, impact on the future. The American experience. Cancer Treat Res. 152:239–262. 2009. View Article : Google Scholar : PubMed/NCBI
40	Martin BT, Kleiber K, Wixler V, Raab M, Zimmer B, Kaufmann M and Strebhardt K: FHL2 regulates cell cycle-dependent and doxorubicin-induced p21Cip1/Waf1 expression in breast cancer cells. Cell Cycle. 6:1779–1788. 2007. View Article : Google Scholar : PubMed/NCBI
41	Li M, Wang J, Ng SS, Chan CY, Chen AC, Xia HP, Yew DT, Wong BC, Chen Z, Kung HF and Lin MC: The four-and-a-half-LIM protein 2 (FHL2) is overexpressed in gliomas and associated with oncogenic activities. Glia. 56:1328–1338. 2008. View Article : Google Scholar : PubMed/NCBI
42	Tanahashi H and Tabira T: Alzheimer's disease-associated presenilin 2 interacts with DRAL, an LIM-domain protein. Hum Mol Genet. 9:2281–2289. 2000. View Article : Google Scholar : PubMed/NCBI
43	Muller JM, Isele U, Metzger E, Rempel A, Moser M, Pscherer A, Breyer T, Holubarsch C, Buettner R and Schüle R: FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J. 19:359–369. 2000. View Article : Google Scholar : PubMed/NCBI
44	Fimia GM, De Cesare D and Sassone-Corsi P: A family of LIM-only transcriptional coactivators: Tissue-specific expression and selective activation of CREB and CREM. Mol Cell Biol. 20:8613–8622. 2000. View Article : Google Scholar : PubMed/NCBI
45	Morlon A and Sassone-Corsi P: The LIM-only protein FHL2 is a serum-inducible transcriptional coactivator of AP-1. Proc Natl Acad Sci USA. 100:3977–3982. 2003. View Article : Google Scholar : PubMed/NCBI
46	Wei Y, Renard CA, Labalette C, Wu Y, Lévy L, Neuveut C, Prieur X, Flajolet M, Prigent S and Buendia MA: Identification of the LIM protein FHL2 as a coactivator of beta-catenin. J Biol Chem. 278:5188–5194. 2003. View Article : Google Scholar : PubMed/NCBI
47	Labalette C, Renard CA, Neuveut C, Buendia MA and Wei Y: Interaction and functional cooperation between the LIM protein FHL2, CBP/p300 and beta-catenin. Mol Cell Biol. 24:10689–10702. 2004. View Article : Google Scholar : PubMed/NCBI
48	Yang Y, Hou H, Haller EM, Nicosia SV and Bai W: Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J. 24:1021–1032. 2005. View Article : Google Scholar : PubMed/NCBI
49	Hamidouche Z, Haÿ E, Vaudin P, Charbord P, Schüle R, Marie PJ and Fromigué O: FHL2 mediates dexamethasone-induced mesenchymal cell differentiation into osteoblasts by activating Wnt/beta-catenin signaling-dependent Runx2 expression. FASEB J. 22:3813–3822. 2008. View Article : Google Scholar : PubMed/NCBI
50	Entz-Werle N, Lavaux T, Metzger N, Stoetzel C, Lasthaus C, Marec P, Kalifa C, Brugieres L, Pacquement H, Schmitt C, et al: Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis. Neoplasia. 9:678–688. 2007. View Article : Google Scholar : PubMed/NCBI
51	Nusse R: Wnt signaling in disease and in development. Cell Res. 15:28–32. 2005. View Article : Google Scholar : PubMed/NCBI